Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pterine SCHEMBL64320 | 0.74 | AKR1B1 (0.54) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL29364680 | 0.74 | AKR1B1 (0.54) | NOS1THRBMITFTP53ALOX15 | |
| SCHEMBL30503663 | 0.74 | THRB (0.49) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL30474634 | 0.73 | AKR1B1 (0.53) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL31190985 | 0.73 | AKR1B1 (0.53) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL31296557 | 0.73 | AKR1B1 (0.53) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL452642 | 0.73 | AKR1B1 (0.53) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL906054 | 0.73 | AKR1B1 (0.53) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL5703596 | 0.73 | AKR1B1 (0.53) | NOS1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL27566961 | 0.73 | AKR1B1 (0.53) | NOS1THRBMITFTP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043688-B2 | Nickel catalysts with two alkali ions for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043689-B2 | Nickel catalysts with single metal cations for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240166775-A1 | NICKEL CATALYSTS WITH TWO METAL CATIONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2024097972-A2 | COMPOUNDS AND METHODS FOR TREATING CANCERS | CEDARS-SINAI MEDICAL CENTER (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3484474-B1 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDRENS MEDICAL CT CORP (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240117076-A1 | NICKEL CATALYSTS WITH SINGLE METAL CATIONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-04-11 | — | — | US | disclosed |
| US-11944625-B2 | Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240101727-A1 | NICKEL CATALYSTS WITH TWO ALKALI IONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240101726-A1 | NICKEL CATALYSTS WITH SINGLE ALKALI IONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-03-28 | — | — | US | disclosed |
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2004000838-A1 | PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| EP-1212302-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944625-B2 | Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | RPS6KA1, RPS6KA2, RPS6KA6 | NOS1 4242/4885THRB 1994/4885MITF 1281/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | NOS1 839/4885THRB 4400/4885MITF 2262/4885 |
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | NOS1 1265/4885THRB 4252/4885MITF 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.